AR007096A1 - MATRIX METALOPROTEASE INHIBITOR COMPOUND METHOD FOR INHIBITING ITS ACTIVITY, A CONTAINING COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL COMPOSITIONS - Google Patents

MATRIX METALOPROTEASE INHIBITOR COMPOUND METHOD FOR INHIBITING ITS ACTIVITY, A CONTAINING COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL COMPOSITIONS

Info

Publication number
AR007096A1
AR007096A1 ARP970101976A ARP970101976A AR007096A1 AR 007096 A1 AR007096 A1 AR 007096A1 AR P970101976 A ARP970101976 A AR P970101976A AR P970101976 A ARP970101976 A AR P970101976A AR 007096 A1 AR007096 A1 AR 007096A1
Authority
AR
Argentina
Prior art keywords
compounds
activity
pharmaceutical compositions
formula
inhibiting
Prior art date
Application number
ARP970101976A
Other languages
Spanish (es)
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of AR007096A1 publication Critical patent/AR007096A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Presenta compuestos que tienen la fórmula (I), donde y es 0, 2 o 3; r es 0-6, Z es (CH2)7- o (CH2)e-C6H4-(CH2)f o donde e es 0-1 y f es 1-6; R15 esH, -Cl, -OMe o de fórmula (II), donde n es 0-4, R17 es C2H5, -alilo, o -bencilo, y R16 esd e fórmula (III), donde t es 0-1, x es 0-4 y R4 es unode los siguientes: haluro, alquilo de 1 a 6 carbonos, OR, NR2, NO2(R=H o alquilo de 1 a 6 carbonos). Estos compuestos son útiles para inhibir lasmetaloproteasas de matriz y, por lo tanto,pa ra combatir los trastornos a los cuales contribuyen las MMP, tales como la osteoartritis, la artritisreumatoidea, la artritits séptica, las enfermedades periodontales, las úlceras de córnea, la proteinuria, la enfermedad deaneurisma a órtico, laepidermólisis vesicular distrófica, los trastornos que producen respuestas inflamatorias, las osteopenias en las que media la actividad de MMP, laenfermedad de la articulación temporomandibular, las enfermedades desmielin izantes del sistema nervioso; las metástasis de tumores o lapérdida degenerativa de cartílago posterior a la lesión articular traumática, y la trombosis coronaria a partir de la ruptura de placa ateroesclerótica.Asimismo se relacionacon un método para inhibir su actividad, con composiciones farmacéuticas y uso de dichos compuestos para prepararcomposiciones farmacéuticas que comprenden una cantidad de un compuesto que sea eficaz para inhibir la actividad de porlo menos una m etaloproteasa dematriz.It presents compounds having the formula (I), where y is 0, 2 or 3; r is 0-6, Z is (CH2) 7- or (CH2) e-C6H4- (CH2) f or where e is 0-1 and f is 1-6; R15 is H, -Cl, -OMe or of formula (II), where n is 0-4, R17 is C2H5, -alyl, or -benzyl, and R16 is of formula (III), where t is 0-1, x is 0-4 and R4 is one of the following: halide, alkyl of 1 to 6 carbons, OR, NR2, NO2 (R = H or alkyl of 1 to 6 carbons). These compounds are useful for inhibiting matrix metalloproteases and thus for combating disorders to which MMPs contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal diseases, corneal ulcers, proteinuria , aortic aneurysm disease, dystrophic vesicular epidermolysis, disorders that produce inflammatory responses, osteopenias mediated by MMP activity, temporomandibular joint disease, demyelinating diseases of the nervous system; tumor metastasis or degenerative cartilage loss after traumatic joint injury, and coronary thrombosis from atherosclerotic plaque rupture. It is also related to a method to inhibit its activity, with pharmaceutical compositions and the use of said compounds to prepare pharmaceutical compositions comprising an amount of a compound that is effective to inhibit the activity of at least one matrix methaloprotease.

ARP970101976A 1996-05-15 1997-05-12 MATRIX METALOPROTEASE INHIBITOR COMPOUND METHOD FOR INHIBITING ITS ACTIVITY, A CONTAINING COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL COMPOSITIONS AR007096A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64838496A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
AR007096A1 true AR007096A1 (en) 1999-10-13

Family

ID=24600568

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101976A AR007096A1 (en) 1996-05-15 1997-05-12 MATRIX METALOPROTEASE INHIBITOR COMPOUND METHOD FOR INHIBITING ITS ACTIVITY, A CONTAINING COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL COMPOSITIONS

Country Status (18)

Country Link
EP (1) EP0912487A1 (en)
JP (1) JP3417951B2 (en)
CN (1) CN1163466C (en)
AR (1) AR007096A1 (en)
AU (1) AU727648B2 (en)
CA (1) CA2253869C (en)
CO (1) CO4990925A1 (en)
HR (1) HRP970246B1 (en)
ID (1) ID20291A (en)
MY (1) MY132470A (en)
PA (1) PA8429401A1 (en)
PE (1) PE65998A1 (en)
SV (1) SV1997000034A (en)
TN (1) TNSN97085A1 (en)
TW (1) TW467892B (en)
WO (1) WO1997043238A1 (en)
YU (1) YU18797A (en)
ZA (1) ZA974032B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
JP5263548B2 (en) * 2007-08-15 2013-08-14 杏林製薬株式会社 A preventive, suppressive or therapeutic agent for cerebral aneurysms containing ibudilast as an active ingredient
CA2944614A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
EP3126339A1 (en) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof
JP2017511319A (en) 2014-04-03 2017-04-20 バイエル ファーマ アクチエンゲゼルシャフト Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970700652A (en) * 1994-01-22 1997-02-12 포올 리틀우드 Metalloproteinase inhibitors

Also Published As

Publication number Publication date
ZA974032B (en) 1998-02-19
WO1997043238A1 (en) 1997-11-20
MY132470A (en) 2007-10-31
CN1225622A (en) 1999-08-11
AU3121997A (en) 1997-12-05
JP3417951B2 (en) 2003-06-16
SV1997000034A (en) 1999-07-05
CA2253869C (en) 2003-04-22
PA8429401A1 (en) 2000-05-24
CA2253869A1 (en) 1997-11-20
CN1163466C (en) 2004-08-25
AU727648B2 (en) 2000-12-21
TW467892B (en) 2001-12-11
CO4990925A1 (en) 2000-12-26
EP0912487A1 (en) 1999-05-06
PE65998A1 (en) 1998-10-20
ID20291A (en) 1998-11-19
HRP970246A2 (en) 1998-04-30
TNSN97085A1 (en) 2005-03-15
YU18797A (en) 1999-11-22
JPH11509870A (en) 1999-08-31
HRP970246B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
ATE89263T1 (en) NAPHTHALINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES536225A0 (en) A PROCEDURE FOR THE PREPARATION OF SULPHAMATES.
ES2056810T3 (en) DERIVATIVES OF PHOSPHINIC ACID.
PT84654B (en) METHOD FOR PREPARING 4-H-1-BENZOPYRANE-4-ONA DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
AR001999A1 (en) DERIVATIVES OF CARBOXYLIC ACID AND COMPOSITIONS CONTAINING THEM, USEFUL AS INHIBITORS OF MATRIX METALOPROTEASE, AND PROCESSES FOR THEIR PREPARATION.
AR007098A1 (en) MATRIX METALOPROTEASE INHIBITORS, COMPOSITIONS UNDERSTANDING THEM, AND USE OF THEM TO PREPARE PHARMACEUTICAL COMPOSITIONS
HN1997000067A (en) SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS
AR007096A1 (en) MATRIX METALOPROTEASE INHIBITOR COMPOUND METHOD FOR INHIBITING ITS ACTIVITY, A CONTAINING COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL COMPOSITIONS
MX9307608A (en) CYTOKINE RELEASE INHIBITORS AND IL-1 ANTAGONISTS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
AR007097A1 (en) BIARYLACETHYLENE MATRIX METALOPROTEASE INHIBITORS, A COMPOSITION THAT HAS MATRIX METALOPROTEASE INHIBITING AND THE USE OF SUCH BIARYLACETILENE IN THE MANUFACTURE OF A MEDICINAL PRODUCT.
AR007100A1 (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED PHENYLALKYL COMPOUNDS AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
BR0008778A (en) Prostaglandin analogs selective for unsaturated fpc16
RU98101090A (en) MONO- AND DISULPHOSE SUBSTITUTED ANTHRAKHINONES AND THEIR APPLICATION FOR TREATMENT OF BONE MATRIX DISORDERS
ECSP972115A (en) SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS
SV1997000038A (en) INHIBITION OF METALOPROTEASE MATRICES BY MEANS OF ACIDS 2- (OMEGA-AROILALKIL) -4-BIARIL-4-OXOBUTIRICO
ECSP972112A (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED FENETILE COMPOUNDS
ECSP972111A (en) MATRIX METALOPROTEINASES INHIBITORS BY ACIDS 2- (AROILALQUIL) -4 BIARIL-4- OXOBUTIRICOS
MX9206042A (en) NEW DERIVATIVES OF TIADIAZINONES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATION CONTAINING THEM
ECSP972114A (en) BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE
NO963369D0 (en) New indan-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
ECSP972113A (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED BIARILOXOBUTIRIC ACIDS
FR2572074B1 (en) THIADIAZOLE DERIVATIVES ACTIVE IN THE CENTRAL NERVOUS SYSTEM, PROCESS FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SE8800846D0 (en) OPTICALLY ACTIVE OXO-ISOINDOLIN DERIVATIVES
BR112022015054A2 (en) METHOD FOR PURIFYING 5-ACETAMIDO-N,N?-BIS(2,3-DI-HYDROXYPROPYL)-2,4,6-TRI-IODOISOPHHATALAMIDE, E, 5-ACETAMIDO-N,N?-BIS(2,3- PURIFIED DI-HYDROXYPROPYL)-2,4,6-TRI-IODOISOPHATALAMIDE
TH19223A (en) Production and use of lactol derivatives

Legal Events

Date Code Title Description
FB Suspension of granting procedure